Search Results

Displaying Results 1-2 of 2 "'PHIO'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight

Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight

clinical and non-clinical stage products, and the key Checkpoint Inhibitor Refractory Cancer companies, including BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma,

More news about: DelveInsight Business Research, LLP

TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight

Feb 02, 2026, 17:31 ET TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight

TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.